Pricing & Reimbursement

Belgium Takes First Step Towards Simplifying Medicines Pricing Procedures

05 Nov 2026 Katrijn Neyt 2 min read
Simpler pricing procedures in Belgium: first phase in force from 9 November 2026, MPCA International

On 30 October 2026, two new implementing decrees were published, marking the first step in the simplification of Belgian medicines pricing regulations. The measures aim to accelerate procedures, reduce administrative burden, and improve the efficiency of pricing dossier assessments.

Key changes include:

  • Greater use of simplified procedures, including for certain parallel-imported medicinal products.
  • Fewer supporting documents required for pricing applications when information is already available through the FAMHP, EMA, or the National Bank of Belgium.
  • The possibility to submit pricing dossiers earlier, based on a positive CHMP opinion.
  • Simplified procedures for implants and hearing aids.

With the exception of one specific measure related to the unit-based pricing of antibiotics, the new rules will enter into force on 9 November 2026.

This reform represents only the first phase of a broader administrative simplification initiative. Additional measures are expected in a second phase, including the potential removal of certain pricing decisions for generics and biosimilars, subject to amendments to NIHDI legislation.

How MPCA Can Help

While these changes create new opportunities for pharmaceutical companies, they also require a thorough understanding of the revised procedures and submission requirements.

MPCA International can support your organisation with:

  • Impact assessments of the new pricing framework for existing and future products.
  • Preparation and review of pricing applications and notifications.
  • Market access and pricing strategy development for innovative medicines, generics, and biosimilars.
  • Identification of opportunities to benefit from accelerated or simplified procedures.
  • Ongoing regulatory intelligence and monitoring of future developments under phase 2 of the reform.

Would you like to understand how these changes may affect your Belgian pricing strategy or ongoing applications? Consult our Pricing & Reimbursement webpage or contact MPCA International to discuss the impact on your product portfolio and regulatory roadmap.

This article is for general information and reflects the situation at the time of writing. Timelines are indicative; always consult the official publications for binding requirements.

Katrijn Neyt

M.P.C.A. International BV — Pharmaceutical Consultancy

Need help navigating the Benelux regulatory landscape?

Our team of specialists is ready to support you — from regulatory strategy and pharmacovigilance to market access and quality assurance.

Your reference partner for Regulatory Affairs, Pharmacovigilance and Quality Affairs in the Benelux. Active since 1998 from Ghent, Belgium.

Accreditations

QP GMP RP GDP RIP EU QPPV/LCP

© 2026 M.P.C.A. International BV  ·  Privacy policy  |  Cookie policy

QP GMP RP GDP RIP EU QPPV/LCP